Host Species:	Goat
Concentration:	1 mg/ml (OD 1.35 / 280 nm)
Antigen:	Human Apolipoprotein CIII
Purification:	Affinity purified
Buffer:	75 mM Sodium Phosphate, 75 mM NaCl, 0.5 mM EDTA, 0.02% NaN3, pH 7.2
Specificity	Specifically binds to human apo CIII. Dilution for immunoblot and ELISA range: 1,000 to 40,000.
Use:	The antibody can be used for detection of apo CIII in plasma and lipoproteins, immunoassays, immunoblots, enzyme conjugation, or biotinylation.
Storage:	-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.

 

*These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.

Importance

Apo CIII contains 79 amino acid residues. The m.w. is 8.7 kDa (Brewer et al., 1974).

It may inhibit the activation of lipoprotein lipase by apo CIII. Apo CIII is a constituent of both apoB- and apoAI-containing lipoproteins in the circulation. Apo CIII plays a pivotal role in regulating the plasma metabolism of VLDL, IDL, and LDL, primarily by inhibiting receptor-mediated uptake of these lipoproteins by the liver (Sehayek and Eisenberg 1991, Aalto-Setala et al., 1992, Zheng et al., 2007)

Brewer, H. B., R. Shulman, P. Herbert, R. Ronan, and K. Wehrly. “The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins.” J Biol Chem 249.15 (1974):4975-84.

Sehayek , E. , and S. Eisenberg . “Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.” J. Biol. Chem. 266 (1991) : 18259 – 18267 .

Aalto-Setala , K., E. A. Fisher , X. Chen , T. Chajek-Shaul , T. Hayek , R. Zechner , A. Walsh , R. Ramakrishnan , H. N. Ginsberg , and J. L. Breslow . “ Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.” J. Clin. Invest. 90 (1992): 1889 – 1900.

Zheng , C. , C. Khoo , K. Ikewaki , and F. M. Sacks . “ Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.” J. Lipid Res. 48 (2007): 1190 -203.

 

Citations

[A12][A13]	2020	Liu, Gang; Zhang, Bo; Hu, Yang; Rood, Jennifer; Liang, Liming; Qi, Lu et al. (2020): Associations of Perfluoroalkyl substances with blood lipids and Apolipoproteins in lipoprotein subspecies: the POUNDS-lost study. In Environmental Health : a global access science source 19 (1), p. 5. DOI: 10.1186/s12940-020-0561-8.
[A12][A13]	2020	Du, Yu; Li, Xingxing; Su, Chunyan; Xi, Mei; Zhang, Xiumin; Jiang, Zhibo et al. (2020): Butyrate protects against high-fat diet-induced atherosclerosis via up-regulating ABCA1 expression in apolipoprotein E-deficiency mice. British Journal of Pharmacology 177 (8), pp. 1754–1772. DOI: 10.1111/bph.14933.
[A12][A13]	2020	Koch, Manja; DeKosky, Steven T.; Goodman, Matthew; Sun, Jiehuan; Furtado, Jeremy D.; Fitzpatrick, Annette L. et al. (2020): Association of Apolipoprotein E in Lipoprotein Subspecies With Risk of Dementia. JAMA Network Open 3 (7), e209250. DOI: 10.1001/jamanetworkopen.2020.9250.
[A12][A13]	2020	Koch, Manja; DeKosky, Steven T.; Goodman, Matthew; Sun, Jiehuan; Furtado, Jeremy D.; Fitzpatrick, Annette L. et al. (2020): High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia. J. Lipid Res. 61 (3), pp. 445–454. DOI: 10.1194/jlr.P119000473.
[A12][A13]	2020	Lee, An-Sheng; Wang, Yu-Chen; Chang, Shih-Sheng; Lo, Ping-Hang; Chang, Chia-Ming; Lu, Jonathan et al. (2020): Detection of a High Ratio of Soluble to Membrane-Bound LOX-1 in Aspirated Coronary Thrombi From Patients With ST-Segment-Elevation Myocardial Infarction. Journal of the American Heart Association 9 (2), e014008. DOI: 10.1161/JAHA.119.014008.
[A12][A13]	2019	Kegulian, Natalie C.; Ramms, Bastian; Horton, Steven; Trenchevska, Olgica; Nedelkov, Dobrin; Graham, Mark J. et al. (2019): ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors. Arterioscler Thromb Vasc Biol. 39 (10), pp. 2145–2156. DOI: 10.1161/ATVBAHA.119.312723.
[A12][A13]	2018	Aroner, Sarah A.; Koch, Manja; Mukamal, Kenneth J.; Furtado, Jeremy D.; Stein, James H.; Tattersall, Matthew C. et al. (2018): High‐Density Lipoprotein Subspecies Defined by Apolipoprotein C‐III and Subclinical Atherosclerosis Measures: MESA (The Multi‐Ethnic Study of Atherosclerosis). In Journal of the American Heart Association 7 (6), p. 40. DOI: 10.1161/JAHA.117.007824.
[A12][A13]	2018	Furtado, Jeremy D.; Yamamoto, Rain; Melchior, John T.; Andraski, Allison B.; Gamez-Guerrero, Maria; Mulcahy, Patrick et al. (2018): Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) Subspecies. In Arterioscler Thromb Vasc Biol. 38 (12), pp. 2827–2842. DOI: 10.1161/ATVBAHA.118.311607.
[A12][A13]	2018	Kim, KyeongJin; Goldberg, Ira J.; Graham, Mark J.; Sundaram, Meenakshi; Bertaggia, Enrico; Lee, Samuel X. et al. (2018): γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor. In Cell Metabolism 27 (4), 816-827.e4. DOI: 10.1016/j.cmet.2018.02.010.
[A12][A13]	2018	Koch, Manja; DeKosky, Steven T.; Fitzpatrick, Annette L.; Furtado, Jeremy D.; Lopez, Oscar L.; Kuller, Lewis H. et al. (2018): Apolipoproteins and Alzheimer"s pathophysiology. In Alzheimer"s & Dementia (Amsterdam, Netherlands) 10, pp. 545–553. DOI: 10.1016/j.dadm.2018.07.001.
[A12][A13]	2018	Morton, Allyson M.; Koch, Manja; Mendivil, Carlos O.; Furtado, Jeremy D.; Tjønneland, Anne; Overvad, Kim et al. (2018): Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk. In JCI Insight 3 (4). DOI: 10.1172/jci.insight.98045.
[A12][A13]	2017	Koch, Manja; Furtado, Jeremy D.; Falk, Kim; Leypoldt, Frank; Mukamal, Kenneth J.; Jensen, Majken K. (2017): Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma. In Alzheimer"s & Dementia (Amsterdam, Netherlands) 6, pp. 182–187. DOI: 10.1016/j.dadm.2017.01.007.
[A12][A13]	2017	Lee, Chan Joo; Choi, Seungbum; Cheon, Dong Huey; Kim, Kyeong Yeon; Cheon, Eun Jeong; Ann, Soo-jin et al. (2017): Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial. In Lipids Health Dis 16 (1), p. 49. DOI: 10.1186/s12944-017-0433-6.
[A12][A13]	2017	Sundaram, Meenakshi; Curtis, Kaitlin R.; Amir Alipour, Mohsen; LeBlond, Nicholas D.; Margison, Kaitlyn D.; Yaworski, Rebecca A. et al. (2017): The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation. In Journal of Lipid Research 58 (11), pp. 2188–2196. DOI: 10.1194/jlr.M077313.
[A12][A13]	2017	Wassef, Hanny; Bissonnette, Simon; Dufour, Robert; Davignon, Jean; Faraj, May (2017): Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women. In J. Nutr. 147 (5), pp. 754–762. DOI: 10.3945/jn.116.242750.
[A12][A13]	2016	Koska, Juraj; Yassine, Hussein; Trenchevska, Olgica; Sinari, Shripad; Schwenke, Dawn C.; Yen, Frances T. et al. (2016): Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. In Journal of Lipid Research 57 (5), pp. 894–905. DOI: 10.1194/jlr.P064816.
[A12][A13]	2015	Trenchevska, Olgica; Schaab, Matthew R.; Nelson, Randall W.; Nedelkov, Dobrin (2015): Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. In Methods (San Diego, Calif.) 81, pp. 86–92. DOI: 10.1016/j.ymeth.2015.02.020.
[A12][A13]	2015	Yassine, Hussein N.; Trenchevska, Olgica; Ramrakhiani, Ambika; Parekh, Aarushi; Koska, Juraj; Walker, Ryan W. et al. (2015): The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides. In PLoS ONE 10 (12), e0144138. DOI: 10.1371/journal.pone.0144138.
[A12][A13]	2014	Lee, An-Sheng; Chen, Wei-Yu; Chan, Hua-Chen; Hsu, Jing-Fang; Shen, Ming-Yi; Chang, Chia-Ming et al. (2014): Gender disparity in LDL-induced cardiovascular damage and the protective role of estrogens against electronegative LDL. In Cardiovascular Diabetology 13, p. 64. DOI: 10.1186/1475-2840-13-64.
[A12][A13]	2014	Talayero, Beatriz; Wang, Liyun; Furtado, Jeremy; Carey, Vincent J.; Bray, George A.; Sacks, Frank M. (2014): Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. In J. Lipid Res. 55 (10), pp. 2167–2177. DOI: 10.1194/jlr.M042333.
[A12][A13]	2014	Wang, Liyun; Sacks, Frank M.; Furtado, Jeremy D.; Ricks, Madia; Courville, Amber B.; Sumner, Anne E. (2014): Racial differences between African-American and white women in insulin resistance and visceral adiposity are associated with differences in apoCIII containing apoAI and apoB lipoproteins. In Nutrition & Metabolism 11 (1), p. 56. DOI: 10.1186/1743-7075-11-56.
[A12][A13]	2013	Sumner, Anne E.; Furtado, Jeremy D.; Courville, Amber B.; Ricks, Madia; Younger-Coleman, Novie; Tulloch-Reid, Marshall K.; Sacks, Frank M. (2013): ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women. In Nutrition & Metabolism 10 (1), p. 73. DOI: 10.1186/1743-7075-10-73.
[A12][A13]	2013	Zheng, Chunyu; Azcutia, Veronica; Aikawa, Elena; Figueiredo, Jose-Luiz; Croce, Kevin; Sonoki, Hiroyuki et al. (2013): Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. In European Heart Journal 34 (8), pp. 615–624. DOI: 10.1093/eurheartj/ehs271.
[A12][A13]	2012	Jensen, Majken K.; Rimm, Eric B.; Furtado, Jeremy D.; Sacks, Frank M. (2012): Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease. In Journal of the American Heart Association 1 (2). DOI: 10.1161/JAHA.111.000232.
[A12][A13]	2012	Krauss, Ronald M.; Wojnooski, Kathleen; Orr, Joseph; Geaney, J. Casey; Pinto, Cathy Anne; Liu, Yang et al. (2012): Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. In J. Lipid Res. 53 (3), pp. 540–547. DOI: 10.1194/jlr.M018010.
[A12][A13]	2012	Wada, Yoshinao; Kadoya, Machiko; Okamoto, Nobuhiko (2012): Mass spectrometry of apolipoprotein C-III, a simple analytical method for mucin-type O-glycosylation and its application to an autosomal recessive cutis laxa type-2 (ARCL2) patient. In Glycobiology 22 (8), pp. 1140–1144. DOI: 10.1093/glycob/cws086.
[A12][A13]	2011	Holmberg, R.; Refai, E.; Hoog, A.; Crooke, R. M.; Graham, M.; Olivecrona, G. et al. (2011): Lowering apolipoprotein CIII delays onset of type 1 diabetes. In J. Biol. Chem. 108 (26), pp. 10685–10689. DOI: 10.1073/pnas.1019553108.
[A12][A13]	2011	Mendivil, Carlos O.; Rimm, Eric B.; Furtado, Jeremy; Chiuve, Stephanie E.; Sacks, Frank M. (2011): Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. In Circulation 124 (19), pp. 2065–2072. DOI: 10.1161/CIRCULATIONAHA.111.056986.
[A12][A13]	2011	Qin, Wen; Sundaram, Meenakshi; Wang, Yuwei; Zhou, Hu; Zhong, Shumei; Chang, Chia-Ching et al. (2011): Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. In J. Biol. Chem. 286 (31), pp. 27769–27780. DOI: 10.1074/jbc.M110.203679.
[A12][A13]	2010	Furtado, Jeremy D.; Campos, Hannia; Sumner, Anne E.; Appel, Lawrence J.; Carey, Vincent J.; Sacks, Frank M. (2010): Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial. In The American Journal of Clinical Nutrition 92 (4), pp. 714–722. DOI: 10.3945/ajcn.2009.28532.
[A12][A13]	2010	Jayanthi, S.; Buie, S.; Moore, S.; Herning, R. I.; Better, W.; Wilson, N. M. et al. (2010): Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses. In Molecular Psychiatry 15 (1), pp. 101–112. DOI: 10.1038/mp.2008.50;
[A12][A13]	2010	Sundaram, Meenakshi; Zhong, Shumei; Bou Khalil, Maroun; Zhou, Hu; Jiang, Zhenghui G.; Zhao, Yang et al. (2010): Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia. In J. Lipid Res. 51 (6), pp. 1524–1534. DOI: 10.1194/jlr.M005108.
[A12][A13]	2010	Sundaram, Meenakshi; Zhong, Shumei; Khalil, Maroun Bou; Links, Philip H.; Zhao, Yang; Iqbal, Jahangir et al. (2010): Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. In J. Lipid Res. 51 (1), pp. 150–161. DOI: 10.1194/jlr.M900346-JLR200.
[A12][A13]	2008	Deng, Ting; Ji, Wei; Lian, Ji-Hong; Guo, Lei; Hu, Wei-Rong; Qian, Ming; Gong, Bang-qiang (2008): Identifying Natural Derived Upregulators of Human ApoA-I Expression via a Cell-Based Drug Screening System. In Pharmaceutical Biology 46 (9), pp. 610–615. DOI: 10.1080/13880200802179584.
[A12][A13]	2008	Furtado, Jeremy D.; Campos, Hannia; Appel, Lawrence J.; Miller, Edgar R.; Laranjo, Nancy; Carey, Vincent J.; Sacks, Frank M. (2008): Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial. In The American Journal of Clinical Nutrition 87 (6), pp. 1623–1630. DOI: 10.1093/ajcn/87.6.1623.
[A12][A13]	2008	Ruiz-Narváez, Edward A.; Sacks, Frank M.; Campos, Hannia (2008): Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction. In The American Journal of Clinical Nutrition 87 (6), pp. 1932–1938. DOI: 10.1093/ajcn/87.6.1932.
[A12][A13]	2007	Kawakami, Akio; Aikawa, Masanori; Nitta, Noriko; Yoshida, Masayuki; Libby, Peter; Sacks, Frank M. (2007): Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. In Arterioscler Thromb Vasc Biol. 27 (1), pp. 219–225. DOI: 10.1161/01.ATV.0000249620.68705.0d.
[A12][A13]	2007	Gaubatz, John W.; Gillard, Baiba K.; Massey, John B.; Hoogeveen, Ron C.; Huang, Max; Lloyd, Eric E. et al. (2007): Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). In J. Lipid Res. 48 (2), pp. 348–357. DOI: 10.1194/jlr.M600249-JLR200.
[A12][A13]	2006	Guo, Lei; Hu, Wei-Rong; Lian, Ji-Hong; Ji, Wei; Deng, Ting; Qian, Ming; Gong, Bang-qiang (2006): Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo. In European Journal of Pharmacology 551 (1-3), pp. 80–86. DOI: 10.1016/j.ejphar.2006.08.048.
[A12][A13]	2006	Kawakami, Akio; Aikawa, Masanori; Alcaide, Pilar; Luscinskas, Francis W.; Libby, Peter; Sacks, Frank M. (2006): Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. In Circulation 114 (7), pp. 681–687. DOI: 10.1161/CIRCULATIONAHA.106.622514.
[A12][A13]	2006	Kawakami, Akio; Aikawa, Masanori; Libby, Peter; Alcaide, Pilar; Luscinskas, Francis W.; Sacks, Frank M. (2006): Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. In Circulation 113 (5), pp. 691–700. DOI: 10.1161/CIRCULATIONAHA.105.591743.
[A12][A13]	2006	Schaap, Frank G.; Nierman, Melchior C.; Berbée, Jimmy F. P.; Hattori, Hiroaki; Talmud, Philippa J.; Vaessen, Stefan F. C. et al. (2006): Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. In J. Lipid Res. 47 (10), pp. 2333–2339. DOI: 10.1194/jlr.M500533-JLR200.
[A12][A13]	2005	Nedelkov, Dobrin; Kiernan, Urban A.; Niederkofler, Eric E.; Tubbs, Kemmons A.; Nelson, Randall W. (2005): Investigating diversity in human plasma proteins. In Proc Natl Acad Sci USA 102 (31), pp. 10852–10857. DOI: 10.1073/pnas.0500426102.
[A12][A13]	2004	Juntti-Berggren, Lisa; Refai, Essam; Appelskog, Ioulia; Andersson, Mats; Imreh, Gabriela; Dekki, Nancy et al. (2004): Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. In Proc Natl Acad Sci USA 101 (27), pp. 10090–10094. DOI: 10.1073/pnas.0403551101.
[A12][A13]	2003	Malek, Goldis; Li, Chuan-Ming; Guidry, Clyde; Medeiros, Nancy E.; Curcio, Christine A. (2003): Apolipoprotein B in Cholesterol-Containing Drusen and Basal Deposits of Human Eyes with Age-Related Maculopathy. In The American Journal of Pathology 162 (2), pp. 413–425. DOI: 10.1016/S0002-9440(10)63836-9.
[A12][A13]	2003	Yang, Chao-Yuh; Raya, Joe L.; Chen, Hsin-Hung; Chen, Chu-Huang; Abe, Yasunori; Pownall, Henry J. et al. (2003): Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. In Arterioscler Thromb Vasc Biol. 23 (6), pp. 1083–1090. DOI: 10.1161/01.ATV.0000071350.78872.C4.
[A12][A13]	2001	Deeg, M. A.; Bierman, E. L.; Cheung, M. C. (2001): GPI-specific phospholipase D associates with an apoA-I- and apoA-IV-containing complex. In J. Lipid Res. 42 (3), pp. 442–451.

academy biomed[A05]绵羊抗人类载脂蛋白AII多克隆抗体12A-S1a学院生物医学公司$ 155.00$ 155.00目录号数量1寄主物种： 羊浓度： 1毫克/毫升（OD 1.35 / 280 nm）抗原： 人类载脂蛋白AII纯化： 亲和纯化缓冲： 75 mM磷酸钠，75 mM NaCl，0.5 mM EDTA，0.02％NaN3，pH 7.2特异性 与人载脂蛋白AII特异性结合。免疫印迹和ELISA的稀释范围：1,000至80,000。用： 该抗体可用于检测血浆和脂蛋白中的载脂蛋白AII，免疫测定，免疫印迹，酶结合或生物素化。存储： -20°C长期保存，4°C短期保存。等分试样，以避免反复冻结和解冻。 *这些产品仅用于研究或制造用途，不能用于人体治疗或诊断应用。 重要性Apo AII占HDL的25％。它在人血浆中以77条氨基酸残基的2条相同链的二聚体形式存在，并通过二硫键连接。据报道，单链的分子量为8.7kDa（Brewer等，1972）。对小鼠的研究报道，apoAII可能具有促动脉粥样硬化作用（Warden等，1993）。然而，一项大型的欧洲前瞻性研究中的病例对照研究表明，血浆Apo AII浓度与冠心病事件密切相关（Birjmohun等，2007）。Birjmohun，RS，GM Dallinga-Thie，JA Kuivenhoven，ESg Stroes，JD Otvos，NJ Wareham，R.Luben，JJp Kastelein，K.-T. Khaw和SM Boekholdt。“载脂蛋白A-II与未来冠状动脉疾病的风险成反比。” 循环116（2007）：2029-035。Brewer，HB，SE Lux，R.Ronan和KM John。“人ApoLp-Gln-II（apoA-II），一种从高密度脂蛋白复合物中分离的载脂蛋白的氨基酸序列。” 美国国家科学院院刊69.5（1972）：1304-308。Warden，C.，C.Hedrick，J.Qiao，L.Castellani和A.Lusis。“过表达载脂蛋白A-II的转基因小鼠中的动脉粥样硬化。” 科学261（1993）：469-72。